Vaccine for treating and/or preventing African swine fever virus and preparation method thereof
A vaccine and sequence technology, applied in the field of vaccines, can solve problems such as economic threats to people's livelihood and the advent of vaccines, and achieve the effects of reducing production costs, rapid research and development, and simple production processes
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0039] In vitro transcription synthesis of embodiment 1 encoding ASFV antigen mRNA
[0040] 1. Reagent source
[0041] Restriction endonucleases BtsaⅠ and EcoRV were purchased from Yubao Bioengineering (Dalian) Co., Ltd., T7 HighYield Transcription Kit and Cap1 Capping System were purchased from Jinan Protein Technology Co., Ltd., and DH5α competent cells were purchased from Nanjing Nuoweizan Biotechnology Co., Ltd., DNA purification and recovery kits, and plasmid extraction kits were purchased from Tiangen Biochemical Technology (Beijing) Co., Ltd., and nucleotide fragment synthesis and carrier connection were completed by Sangon Bioengineering (Shanghai) Co., Ltd.
[0042] 2. Synthesis of nucleotide fragments and carrier ligation
[0043]Import the nucleotide sequence SEQ ID NO.6 data encoding the P72 protein (its amino acid sequence is SEQ ID NO.7) into the DNAstar software for sequence analysis, and perform homology with the DNA sequence obtained in the gene bank of NCBI ...
Embodiment 2
[0054] Embodiment 2 ASFV mRNA eukaryotic expression
[0055] 1. Reagent source
[0056] The mRNA prepared in embodiment 1, Lipofectamine TM 3000 was purchased from Thermo Fisher Scientific (China) Co., Ltd., ASFV positive serum was purchased from Qingdao Ruier Biotechnology Co., Ltd., HRP-labeled rabbit anti-pig IgG, and highly sensitive ECL luminescent reagent were purchased from Sangon Bioengineering (Shanghai) Co., Ltd.
[0057] 2. ASFV mRNA transfection 293T cell operation steps
[0058] The 239T cells that can grow stably were selected for six-well plates for plating, and transfection was performed when the cells grew to 60-70%. First, the mRNA encoding P72 protein and the mRNA encoding CAP80 protein were mixed at a mass fraction ratio of 2:1; then transfected according to the instructions of lip3000. First prepare liquid A and liquid B; liquid A: dilute 4 μg mRNA with 200 μL Opti-MEM; liquid B: dilute 10 μl lipo2000 with 200 μl Opti-MEM, mix liquid A and liquid B ge...
Embodiment 3
[0061] Example 3 LNP-mRNA vaccine production
[0062] 1. Reagent source
[0063] The mRNA prepared in Example 1, DLin-MC3-DMA, cholesterol, DSPC, and polyethylene glycol were purchased from Aiweituo (Shanghai) Pharmaceutical Technology Co., Ltd., and protamine was purchased from Sangon Bioengineering (Shanghai) Co., Ltd. Co., absolute ethanol, ammonium citrate buffer.
[0064] 2. The operation process of vaccine preparation
[0065] Dissolve ionizable lipid (DLin-MC3-DMA), cholesterol, auxiliary lipid (DSPC), and polyethylene glycol in absolute ethanol according to the ratio of 50%, 29%, 20%, and 1%, and the total concentration is at 5-7mg / ml, constitute the organic phase; mix the mRNA encoding ASFV P72 protein and the mRNA encoding ASFV CAP80 protein at a mass fraction of 1:2, then add 0.05% protamine and mix evenly, with 0.8-1.2mg The total concentration per ml is dissolved in sodium citrate buffer to form the aqueous phase; the organic phase and the aqueous phase are mix...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


